Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Sullivan

Showing results (171-180 of 327) with videos related to

Pageof 33
Sort By:
The Oncologist|October 12, 2020
Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient SettingSienna M Durbin, Leyre Zubiri, Andrzej Niemierko, et al.
Annals of Surgical Oncology|June 5, 2026
ASO Visual Abstract: Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy ResponseAleigha Lawless, Derek N Effiom, Alma Burbano, et al.
Journal of the American Academy of Dermatology|February 22, 2022
Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanomaMaria S Asdourian, Tracey S Otto, Ted V Jacoby, et al.
JCO Precision Oncology|January 18, 2024
Detection of Copy-Number Variation in Circulating Cell-Free DNA in Patients With Uveal MelanomaTakuto Sato, Kamaneh Montazeri, Evangelos S Gragoudas, et al.
Nature Medicine|June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patientsRyan J Sullivan, Omid Hamid, Rene Gonzalez, et al.
Annals of Surgical Oncology|May 23, 2026
Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy ResponseAleigha Lawless, Derek N Effiom, Alma Burbano, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 23, 2020
Clinical features of acute kidney injury in patients receiving dabrafenib and trametinibHarish Seethapathy, Meghan D Lee, Ian A Strohbehn, et al.
Journal of the American Heart Association|November 16, 2020
Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated MyocarditisZsofia D Drobni, Amna Zafar, Leyre Zubiri, et al.
Cancer Immunology Research|March 5, 2015
Impact of NRAS mutations for patients with advanced melanoma treated with immune therapiesDouglas B Johnson, Christine M Lovly, Marisa Flavin, et al.
Journal for Immunotherapy of Cancer|November 13, 2021
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trialPatrick A Ott, Matthew Nazzaro, Kathleen L Pfaff, et al.
Pageof 33

Showing results (171-180 of 327) with videos related to

Sort By:
Pageof 33
The Oncologist|October 12, 2020
Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient SettingSienna M Durbin, Leyre Zubiri, Andrzej Niemierko, et al.
Annals of Surgical Oncology|June 5, 2026
ASO Visual Abstract: Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy ResponseAleigha Lawless, Derek N Effiom, Alma Burbano, et al.
Journal of the American Academy of Dermatology|February 22, 2022
Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanomaMaria S Asdourian, Tracey S Otto, Ted V Jacoby, et al.
JCO Precision Oncology|January 18, 2024
Detection of Copy-Number Variation in Circulating Cell-Free DNA in Patients With Uveal MelanomaTakuto Sato, Kamaneh Montazeri, Evangelos S Gragoudas, et al.
Nature Medicine|June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patientsRyan J Sullivan, Omid Hamid, Rene Gonzalez, et al.
Annals of Surgical Oncology|May 23, 2026
Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy ResponseAleigha Lawless, Derek N Effiom, Alma Burbano, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 23, 2020
Clinical features of acute kidney injury in patients receiving dabrafenib and trametinibHarish Seethapathy, Meghan D Lee, Ian A Strohbehn, et al.
Journal of the American Heart Association|November 16, 2020
Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated MyocarditisZsofia D Drobni, Amna Zafar, Leyre Zubiri, et al.
Cancer Immunology Research|March 5, 2015
Impact of NRAS mutations for patients with advanced melanoma treated with immune therapiesDouglas B Johnson, Christine M Lovly, Marisa Flavin, et al.
Journal for Immunotherapy of Cancer|November 13, 2021
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trialPatrick A Ott, Matthew Nazzaro, Kathleen L Pfaff, et al.
Pageof 33